Terms: = Pancreatic cancer AND SPOP, TEF2, 8405, ENSG00000121067, O43791
17 results:
1. BCLAF1 binds spop to stabilize PD-L1 and promotes the development and immune escape of hepatocellular carcinoma.
Yu Z; Wu X; Zhu J; Yan H; Li Y; Zhang H; Zhong Y; Lin M; Ye G; Li X; Jin J; Li K; Wang J; Zhuang H; Lin T; He J; Lu C; Xu Z; Zhang X; Li H; Jin X
Cell Mol Life Sci; 2024 Feb; 81(1):82. PubMed ID: 38340178
[TBL] [Abstract] [Full Text] [Related]
2. CSN6-spop-HMGCS1 Axis Promotes Hepatocellular Carcinoma Progression via YAP1 Activation.
Li K; Zhang J; Lyu H; Yang J; Wei W; Wang Y; Luo H; Zhang Y; Jiang X; Yi H; Wang M; Zhang C; Wu K; Xiao L; Wen W; Xu H; Li G; Wan Y; Yang F; Yang R; Fu X; Qin B; Zhou Z; Zhang H; Lee MH
Adv Sci (Weinh); 2024 Apr; 11(14):e2306827. PubMed ID: 38308184
[TBL] [Abstract] [Full Text] [Related]
3. Mutation-Attention (MuAt): deep representation learning of somatic mutations for tumour typing and subtyping.
Sanjaya P; Maljanen K; Katainen R; Waszak SM; ; Aaltonen LA; Stegle O; Korbel JO; Pitkänen E
Genome Med; 2023 Jul; 15(1):47. PubMed ID: 37420249
[TBL] [Abstract] [Full Text] [Related]
4. TRABID overexpression enables synthetic lethality to PARP inhibitor via prolonging 53BP1 retention at double-strand breaks.
Ma J; Zhou Y; Pan P; Yu H; Wang Z; Li LL; Wang B; Yan Y; Pan Y; Ye Q; Liu T; Feng X; Xu S; Wang K; Wang X; Jian Y; Ma B; Fan Y; Gao Y; Huang H; Li L
Nat Commun; 2023 Mar; 14(1):1810. PubMed ID: 37002234
[TBL] [Abstract] [Full Text] [Related]
5. Determination of ERG(+), EZH2, NKX3.1, and SPINK-1 subtypes to evaluate their association with clonal origin and disease progression in multifocal prostate cancer.
Segura-Moreno YY; Sanabria-Salas MC; Mesa-López De Mesa JA; Varela-Ramirez R; Acosta-Vega NL; Serrano ML
Cancer Rep (Hoboken); 2023 Feb; 6(2):e1728. PubMed ID: 36199157
[TBL] [Abstract] [Full Text] [Related]
6. Collision tumors revealed by prospectively assessing subtype-defining molecular alterations in 904 individual prostate cancer foci.
Fontugne J; Cai PY; Alnajar H; Bhinder B; Park K; Ye H; Beg S; Sailer V; Siddiqui J; Blattner-Johnson M; Croyle JA; Noorzad Z; Calagua C; MacDonald TY; Axcrona U; Bogaard M; Axcrona K; Scherr DS; Sanda MG; Johannessen B; Chinnaiyan AM; Elemento O; Skotheim RI; Rubin MA; Barbieri CE; Mosquera JM
JCI Insight; 2022 Feb; 7(4):. PubMed ID: 35050902
[TBL] [Abstract] [Full Text] [Related]
7. spop suppresses testicular germ cell tumors progression through ubiquitination and degradation of DPPA2.
Wang J; Zhuang H; Zhang H; Li Q; Cao X; Lin Z; Lin T; Chen X; Ni X; Yang J; Zhao Y; Shen L; Wang H; Zhu J; Ye M; Jin X
Biochem Biophys Res Commun; 2021 Jun; 557():55-61. PubMed ID: 33862460
[TBL] [Abstract] [Full Text] [Related]
8. CRL3-spop ubiquitin ligase complex suppresses the growth of diffuse large B-cell lymphoma by negatively regulating the MyD88/NF-κB signaling.
Jin X; Shi Q; Li Q; Zhou L; Wang J; Jiang L; Zhao X; Feng K; Lin T; Lin Z; Zhuang H; Yang J; Hu C; Zhang L; Shen L; Lu Y; Zhu J; Wang H; Qi H; Meng X; Xi Y; Pan J; Fang S; Tian H; Zhou C; Zhang P; Gao K; Zhao SM; Li Y; Gong Z; Wang C
Leukemia; 2020 May; 34(5):1305-1314. PubMed ID: 31776466
[TBL] [Abstract] [Full Text] [Related]
9. spop suppresses pancreatic cancer progression by promoting the degradation of NANOG.
Tan P; Xu Y; Du Y; Wu L; Guo B; Huang S; Zhu J; Li B; Lin F; Yao L
Cell Death Dis; 2019 Oct; 10(11):794. PubMed ID: 31624231
[TBL] [Abstract] [Full Text] [Related]
10. Molecular Underpinnings Governing Genetic Complexity of ETS-Fusion-Negative Prostate cancer.
Bhatia V; Ateeq B
Trends Mol Med; 2019 Nov; 25(11):1024-1038. PubMed ID: 31353123
[TBL] [Abstract] [Full Text] [Related]
11. DUB3 Promotes BET Inhibitor Resistance and cancer Progression by Deubiquitinating BRD4.
Jin X; Yan Y; Wang D; Ding D; Ma T; Ye Z; Jimenez R; Wang L; Wu H; Huang H
Mol Cell; 2018 Aug; 71(4):592-605.e4. PubMed ID: 30057199
[TBL] [Abstract] [Full Text] [Related]
12. Speckle-type POZ protein suppresses hepatocellular carcinoma cell migration and invasion via ubiquitin-dependent proteolysis of SUMO1/sentrin specific peptidase 7.
Ji P; Liang S; Li P; Xie C; Li J; Zhang K; Zheng X; Feng M; Li Q; Jiao H; Chi X; Zhao W; Zhang S; Wang X
Biochem Biophys Res Commun; 2018 Jul; 502(1):30-42. PubMed ID: 29777712
[TBL] [Abstract] [Full Text] [Related]
13. Molecular alterations in prostate cancer and association with MRI features.
Lee D; Fontugne J; Gumpeni N; Park K; MacDonald TY; Robinson BD; Sboner A; Rubin MA; Mosquera JM; Barbieri CE
Prostate Cancer Prostatic Dis; 2017 Dec; 20(4):430-435. PubMed ID: 28762374
[TBL] [Abstract] [Full Text] [Related]
14. Dysregulation of INF2-mediated mitochondrial fission in spop-mutated prostate cancer.
Jin X; Wang J; Gao K; Zhang P; Yao L; Tang Y; Tang L; Ma J; Xiao J; Zhang E; Zhu J; Zhang B; Zhao SM; Li Y; Ren S; Huang H; Yu L; Wang C
PLoS Genet; 2017 Apr; 13(4):e1006748. PubMed ID: 28448495
[TBL] [Abstract] [Full Text] [Related]
15. Molecular Discriminators of Racial Disparities in Prostate cancer.
Ateeq B; Bhatia V; Goel S
Trends Cancer; 2016 Mar; 2(3):116-120. PubMed ID: 28741531
[TBL] [Abstract] [Full Text] [Related]
16. Molecular foundations for personalized therapy in prostate cancer.
Fisher KW; Montironi R; Lopez Beltran A; Moch H; Wang L; Scarpelli M; Williamson SR; Koch MO; Cheng L
Curr Drug Targets; 2015; 16(2):103-14. PubMed ID: 25547910
[TBL] [Abstract] [Full Text] [Related]
17. Evidence for molecular differences in prostate cancer between African American and Caucasian men.
Khani F; Mosquera JM; Park K; Blattner M; O'Reilly C; MacDonald TY; Chen Z; Srivastava A; Tewari AK; Barbieri CE; Rubin MA; Robinson BD
Clin Cancer Res; 2014 Sep; 20(18):4925-34. PubMed ID: 25056375
[TBL] [Abstract] [Full Text] [Related]
